Clinical Performance Evaluation of T-TAS®01 HD Chip

Healthy Donors: Inclusion Criteria: * Males and females age 18 years or older. * Able and willing to provide written informed consent. Exclusion Criteria: * Hospitalization or doctor's visits within prior 30 days, except for routine checkup/physical examination. * Use of antiplatelet therapy within the past 14 days, e.g. aspirin, clopidogrel, prasugrel, ticagrelor, cilostazol. * Use of anticoagulant drugs within the past 14 days, e.g. heparin, bivalirudin, warfarin, rivaroxaban, and apixaban. * Use of certain nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit COX-1 such as rofecoxib, etc. within the past 14 days, unless confirmed to not inhibit platelet activity (such as celecoxib). * History of anemia. * Known thrombocytopenia (platelet count \< 100,000/μL). * Significant renal dysfunction (eGFR \< 30 mL/min/1.73 m2) or dialysis. * History of platelet disorders e.g. von Willebrand factor deficiency, Glanzmann's thrombasthenia or Bernard-Soulier syndrome. * History of hemophilia or bleeding disorders. * History of clinically significant bleeding requiring physician consultation or visit to healthcare facility. * Females who are in the last trimester of pregnancy or are breastfeeding. * Known active gastrointestinal disease including peptic ulcers, gastro-esophageal reflux disease (GERD), and hyperacidity. * Currently participating in a study involving an investigational drug or compound known to affect coagulation or hemostasis. * Subjects with significant past medical history as determined by the Investigator that would pose safety concerns or interfere with the study goals. Thrombocytopenia Patients Inclusion Criteria: * Males and females age 18 years or older. * Known thrombocytopenia, which may be attributed to any of the following: * Immune thrombocytopenia (ITP) * Lupus * Rheumatoid arthritis * Aplastic anemia * Thrombotic thrombocytopenic purpura (TTP) * Disseminated intravascular coagulation (DIC) * Heparin induced thrombocytopenia (HIT) * Vaccine-induced thrombotic thrombocytopenia (VITT) * Infection * Surgery * Cancer * Other etiologies including trauma, portal hypertension, liver disease, etc. * Platelet count \< 90,000/μL, confirmed by pre-transfusion CBC * Planned platelet transfusion. * Able and willing to provide written informed consent Exclusion Criteria: * Use of antiplatelet therapy within the past 14 days, e.g. aspirin, clopidogrel, prasugrel, ticagrelor, cilostazol, abciximab, eptifibatide within the past 14 days. * Use of certain nonsteroidal anti-inflammatory drugs (NSAIDs) known to affect platelet function such as rofecoxib, etc. within the past 14 days, unless confirmed to not inhibit platelet activity (such as celecoxib). * Surgical procedure on the same day as the baseline blood sample collection and testing * Surgical procedure after baseline sample collection and testing, and prior to completion of all post-transfusion blood sample collection and testing * Significant renal dysfunction (eGFR \< 30 mL/min/1.73 m2) or dialysis. * History of platelet disorders e.g. von Willebrand factor deficiency, Glanzmann thrombasthenia or Bernard-Soulier syndrome. * History of hemophilia or bleeding disorders. * Females who are in the last trimester of pregnancy or are breastfeeding. * Known active gastrointestinal disease including peptic ulcers, gastro-esophageal reflux disease (GERD), and hyperacidity. * Currently participating in a study involving an investigational drug or compound known to affect coagulation or hemostasis. * Subjects with significant past medical history as determined by the Investigator that would pose safety concerns or interfere with the study goals.